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Introduction:The amygdala is implicated in psychiatric illness. Even as the amygdala
undergoes significant atrophy in mild dementia, amygdala volume is underexplored as a
risk factor for neuropsychiatric symptoms (NPS).
Objective : To analyze the association between baseline amygdala volume and the
longitudinal trajectories of NPS and cognitive decline in Alzheimer’s disease (AD) and
dementia with Lewy bodies (DLB) over 5 years.
Methods: Eighty-nine patients with mild dementia were included (AD = 55;
DLB = 34). Amygdala volume was segmented from structural magnetic resonance
images (sMRI) using a semi-automatic method (Freesurfer 6.0) and normalized by
intracranial volumes. The intracranial volume-normalized amygdala was used as a
predictor of the Neuropsychiatric Inventory (NPI) total score, ordinal NPI item scores
(0 = absence of symptoms, 1–3 = mild symptoms, ≥4 = clinically relevant symptoms),
and Mini-Mental State Examination (MMSE) as measured annually over 5 years using
gamma, ordinal, and linear mixed-effects models, respectively. The models were
adjusted for demographic variables, diagnosis, center of sMRI acquisition, and cognitive
performance. Multiple testing-corrected p-values (q-values) are reported.
Results: Larger intracranial volume-normalized amygdala was associated with less
agitation/aggression (odds ratio (OR) = 0.62 [0.43, 0.90], p = 0.011, q = 0.038) and
less MMSE decline per year (fixed effect = 0.70, [0.29, 1.03], p = 0.001, q = 0.010) but
more depression (OR = 1.49 [1.09, 2.04], p = 0.013, q = 0.040).
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Conclusions: Greater amygdala volume in mild dementia is associated with lower odds
of developing agitation/aggression, but higher odds of developing depression symptoms
during the 5-year study period.
Keywords: magnetic resonance imaging, amygdala, neuropsychiatric symptoms, Alzheimer’s disease, dementia
with lewy bodies
INTRODUCTION
Among structural imaging markers for neurodegenerative
dementias, the hippocampal volume has been extensively
investigated in Alzheimer’s disease (AD) and dementia
with Lewy bodies (DLB) (1, 2). Clinical correlates of
hippocampal atrophy include disease progression and
decline in various cognitive functions, for instance,
episodic memory impairment in AD (3, 4). However,
much less is known about medial temporal lobe
structures of the limbic system such as the amygdala,
localized in the anterior portion of the medial temporal
lobe (5, 6).
Multicenter studies using structural magnetic resonance
imaging (sMRI) have reported that the extent of the atrophy in
the amygdala seems to be comparable to hippocampal atrophy
in patients with mild AD (7). Nevertheless, the amygdala
volume has received less attention than hippocampal volume,
even as amygdala volume also predicts AD progression
(8), and is associated with cognitive performance (9).
Importantly, the amygdala is an essential structure for emotion
regulation and is part of the salience neural network (9).
Of note, several systematic reviews and meta-analyses have
linked amygdala structure and function with psychiatric
disorders such as major depressive disorder, depression with
comorbid anxiety, schizophrenia, and bipolar disorder (10–
13). However, the role of the amygdala as a potential marker of
neuropsychiatric symptoms (NPS) during the course of dementia
remains elusive.
A few cross-sectional studies have suggested associations
between the amygdala volume and NPS in AD, including
aberrant motor behavior (7), irritability, aggression/agitation
(14), anxiety (15), and apathy (16). In spite of it, less is
known about these relationships in the early stage of dementia.
Furthermore, as NPS fluctuate considerably (17, 18), it is essential
to evaluate these associations in longitudinal studies. Especially
in DLB, this association has not been studied as far as we
know. Understanding such association is important to elucidate
the role of early patterns of volume reduction that could
be relevant markers of the risk of NPS in clinical practice,
which could help to implement specific interventions in at-
risk patients.
Based on previous reports in AD showing that amygdala
lesions are involved in NPS (9, 19), and considering our
preliminary findings that NPS are common and fluctuate during
the course of AD and DLB (17, 18), here we aimed to analyze
the association between amygdala volumes and the longitudinal
development of NPS in AD and DLB.
MATERIALS AND METHODS
Study Design and Setting
This is a secondary analysis of the “The Dementia Study of
Western Norway” (DemVest) cohort (20). The latter included
patients with mild dementia due to different etiologies recruited
between 2005 and 2007 across all the dementia clinics in
Hordaland and Rogaland counties in Norway. All patients had
annual follow-up until death. Exclusion criteria consisted of
absence of dementia, moderate or severe dementia, delirium,
personal history of bipolar or psychotic disorder, terminal illness,
or recently diagnosed major somatic disease. Details of the
design, recruitment, and assessments are stated elsewhere (20).
The study was approved by the regional ethics committee and
the Norwegian authorities. All patients signed informed consent
before enrollment in the study.
In the current analysis, we did not include patients with other
causes of dementia recruited in the DemVest cohort (n = 26)
since segmentation of sMRI was only available for AD and DLB
patients; more details about imaging availability can be found
elsewhere (21).
Sample
Only subjects with an available baseline high-resolution sMRI
were included. Thus, we included a total sample of 89 subjects
with mild dementia who had a clinical diagnosis of AD (n =
55) or DLB (n = 34). Data from the first 5 years (i.e., Baseline
+ 5 annual follow-ups) of the DemVest study were used in the
current study.
Clinical Assessment
Four clinical specialists independently applied diagnostic criteria.
Dementia diagnosis was mainly established using the DSM-
IV criteria (22). When non-amnesic features were present,
diagnosis of dementia was made through consensus based
on the DLB operationalized diagnostic criteria (23). Subjects
were further classified as AD (according to the National
Institute of Neurological and Communicative Disorders, Stroke-
Alzheimer’s Disease and Related Disorders Association) (24) or
DLB (according to the International consensus criteria) (23).
Patients with a Mini-Mental State Examination (MMSE) (25)
score ≥20 or a Clinical Dementia Rating scale (CDR) (26) global
score equal to 1 were considered to have a mild stage of dementia.
A subset (AD = 36; DLB = 20) had autopsy confirmation.
High congruency between the clinical, imaging, and
neuropathological diagnosis was achieved as previously
reported (20, 27). Diagnosis was re-assessed regularly during the
follow-up by four specialists in geriatric medicine and psychiatry.
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The final diagnosis (used for analysis in the current study) was
based on the last consensus diagnosis, considering clinical
and imaging findings but giving priority to neuropathological
diagnosis when available.
Annual structured medical evaluations, relevant information
regarding past medical history and medical records were used to
obtain complete and detailed medical background.
Global cognition was assessed using the MMSE score.
NPS Assessment
NPS were assessed annually over 5 years with the
Neuropsychiatric Inventory (NPI) (28). The NPI was based
on the carer report and includes 10 items (in its original
version) for various NPS (i.e., Delusions, Hallucinations,
Agitation/aggression, Dysphoria/depression, Anxiety,
Euphoria/elation, Apathy/indifference, Disinhibition,
Irritability/lability, and Aberrant motor behavior). Each
symptom is rated in severity (ranging 0–3) and frequency
of presentation (ranging 0–4). Thus, multiplying severity by
frequency, a resulting item score (or domain score) can be
obtained for each symptom (ranging 0–12).
For our analyses, item scores ≥ 4 were considered
“clinically relevant symptoms,” item scores between 1
and 3 were considered “mild symptoms,” and item scores
= 0 were considered “absence of symptoms” following
previously reported methods (17, 18, 29–32). Thus,
individual trajectories of NPS were estimated for each
of the NPI domains, based on the item scores (and NPI
total score) of each patient at each time point of the study
(i.e., Baseline+ 5 annual follow-ups).
Amygdala Volumes Segmentation
Baseline sMRI were acquired in three different research centers
using 1.5-T scanners at the three involved research centers
(Philips Intera in Stavanger and Haugesund, and General Electric
Signa Excite in Bergen), with a voxel resolution of 1 × 1 × ≈
1.5mm. Detailed sMRI protocols for each center were available
elsewhere (21). The sMRI were acquired in coronal planes in the
three research centers. Images with artifacts on visual inspection
were excluded. The standardized processing pipeline from
FreeSurfer 6.0 (http://surfer.nmr.mgh.harvard.edu/) was applied
to multicenter sMRI data as follows: movement correction,
non-brain tissues removal, automated calculation of Talairach
transformation, intensity normalization, subcortical white and
gray matter segmentation, cortex boundary tessellation, fully
automatic topology correction, and surface deformation to
determine CSF/gray matter and gray/white matter boundaries
(33–35). For amygdala segmentation and volume calculation,
the FreeSurfer 6.0 automated pipeline for subcortical structures
segmentation was implemented. A detailed explanation of the
FreeSurfer 6.0 subcortical segmentation methods can be found
elsewhere (33). Visual inspection of the final Freesurfer amygdala
segmentation was conducted by one researcher blinded to
diagnosis for accuracy verification. The right and left amygdala
volumes of each hemisphere were summed to obtain the
total amygdala volume. To control for the effect of head
size and gender differences, the intracranial volume-normalized
amygdala was estimated as follows: [Total amygdala volume
in mm3/total intracranial volume in mm3] ∗ 100%, based
on previously published evidence and recommendations on
studying the amygdala volume in neurodegenerative diseases
(36, 37).
Statistical Analysis
Baseline demographic (i.e., age, gender, and years of education)
and sMRI variables were compared between the AD and DLB
subgroups using independent samples t-test for continuous
variables and Chi-square test for categorical variables. Diagnosis-
related differences in the intracranial volume-normalized
amygdala were adjusted using ANCOVA followed by post-
hoc pairwise Tukey test given the possible confounder
effect of covariates such as gender, age, and center of sMRI
acquisition. Non-parametric subgroup differences in clinical
variables (i.e., MMSE, and NPI total) were examined using the
Mann–Whitney U-test.
To assess the trajectories of NPS, each NPI item score (i.e.,
frequency × severity) was collapsed into an ordinal variable
with three levels that indicate the “absence of symptoms” (NPI
item score = 0), “mild symptoms” (NPI item score = 1–3), or
“clinically relevant symptoms” (NPI item score ≥ 4). Frequency
plots for clinically relevant symptoms were created overall and by
diagnosis subgroup.
As repeated observations of individuals are not independent
(i.e., correlated), and each patient had a subject-specific trajectory
of NPS over time (varying not only in the baseline NPS), mixed-
effects models were used to estimate the mean of per-person
means over 5 years. Mixed-effects models consider the mean
population response for ordinal NPI domains over time (fixed
effect), as well as the error in that trajectory associated with
differences in patient characteristics (random effect). Detailed
revision of the application of mixed models in medicine can be
found elsewhere (38).
After the exploratory analysis of our dataset, the center of
sMRI acquisition was observed as a possible source of variability
in demographic and volumetric variables across individuals
(supplementary Figures 1, 2 and supplementary tables 1, 2).
Therefore, subsequent analyses (i.e., mixed-effects models)
included this factor as covariate. Time in the study was also
included as a covariate, and the random effects of time were
also considered.
For statistical purposes, the intracranial volume-normalized
amygdala values were rescaled, multiplying them by 1,000
to avoid the boundary value problem in the subsequent
models’ estimations.
First, to analyze the associations between amygdala volumes
and global NPS in the total sample, we conducted generalized
mixed-effects models. In these models, the intracranial volume-
normalized amygdala was used as the independent variable and
the absolute NPI total score at each time point of the study
was used as the dependent variable (added a constant of one to
obtain a strictly positive distribution). These generalized mixed-
effects models were based on gamma distribution with random
intercepts and slopes in an unstructured variance–covariance
matrix. Time in study, center of sMRI acquisition, gender,
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TABLE 1 | Baseline characteristics of the AD and DLB subgroups.
Total sample (N = 89) AD(N = 55) DLB (N = 34) p-value Adjusted p-value b
Age 75.4 (7.17) 74.9 (7.28) 76.3 (7.01) 0.383 -
Gender <0.001 -
Women (%) 53 (59.55) 41 (74.55) 12 (35.29) - -
Men (%) 36 (40.45) 14 (25.45) 22 (64.71) - -
Years of education 9.5 (2.79) 9.5 (2.55) 9.4 (3.02) 0.864 -
MMSE a 24 (2.62) 24 (3) 24 (5) 0.966 -
NPI total a 12 (17) 8 (16.5) 16.5 (16) 0.006 -
Amygdala (% ICV) 0.154 (0.042) 0.152 (0.045) 0.158 (0.039) 0.487 0.569
AD, Alzheimer’s disease; DLB, Dementia with Lewy bodies; SD, Standard deviation; IQR, Interquartile range; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric inventory;
ICV, Total intracranial volume.
Values are presented as mean (SD), and frequency (%) for gender.
p < 0.05 are printed in bold.
aValues are presented as median (IQR), Mann–Whitney U.
bANCOVA (df = 6), controlling for age, gender, and center of sMRI acquisition with post-hoc Tukey pairwise test by diagnosis.
diagnosis, and MMSE total score were included as covariates in a
fully adjusted model.
Second, we conducted separate ordinal mixed-effects
models using intracranial volume-normalized amygdala as
the independent variable and each of the ordinal NPI items
(i.e., delusions, hallucinations, agitation/aggression, depression,
anxiety, apathy, disinhibition, irritability, and aberrant motor
behavior) at each time point of the study as the outcome variable.
Euphoria was not included in analyses due to its low frequency
and thus lack of power in this study to detect any relevant
finding. We again used random intercepts and slopes in an
unstructured variance–covariance matrix. All these models were
conducted as unadjusted, partly adjusted, and fully adjusted
models as follows: The unadjusted models included time and
center of sMRI acquisition as covariates. The partly adjusted
models also included age, gender, and diagnosis as covariates.
The fully adjusted models included the same above covariates
as well as longitudinal MMSE scores (i.e., the absolute score of
MMSE at each time point of the study). All models included any
significant interactions.
Considering potential confounder effects of MMSE on the
NPI total and the NPI items estimations, we also examined the
associations between intracranial volume-normalized amygdala
(independent variable) and the absolute score of MMSE at
each study time point (dependent variable) using linear mixed-
effects models. Again, we included random intercepts and
slopes in an unstructured variance–covariance matrix. This
unadjusted model included time and center of sMRI as
covariates, and an adjusted model included also age, gender,
and diagnosis.
Time interactions with intracranial volume-normalized
amygdala were also evaluated in the NPI total score and the
MMSE models based on the Akaike Information Criterion (AIC)
and the Bayesian Information Criterion (BIC). Significant time ∗
diagnosis, time ∗ MMSE, and time ∗ NPI total score interactions
were considered for analysis.
Effect sizes are reported as fixed effects (FE, for NPI total score
and MMSE) and odds ratios (OR, for each of the NPI items).
The resulting p-values of the predictors in all the above
mixed-effects models were corrected for multiple testing using
the false discovery rate (FDR) (39). Given the dependence of
these p-values, we used a tail-area-based FDR (40). The statistical
significance level was defined as alpha = 0.05 for all analyses.
FDR-adjusted p-values (q-values) are reported.
Missing data during follow-up, mostly due to death, were
assumed to be missing at random, supported by previous
publications showing that age, gender, diagnosis, and cognitive
decline all predict mortality in this cohort (41).
Additional exploratory analyses for ordinal NPI items, NPI
total, and MMSE were conducted stratified by diagnosis. Given
the small sample size of each subgroup, these models only
included time and center as covariates. Also, considering the
exploratory nature of analyses, the resulting p-values were not
corrected for multiple testing.
Statistical analyses were performed using Stata © version 15.1.
RStudio © version 1.1.456 was used for the FDR correction
(fdrtool package) and illustrations (ggplot2, seaborn) (40–43).
The current study is reported following the Strengthening the




A total of 89 patients with mild dementia were included
(AD = 55; DLB =34). Demographic and clinical baseline
characteristics, as well as the intracranial volume-normalized
amygdala, are presented in Table 1. At baseline, age and MMSE
were comparable in AD and DLB subgroups. There were
significant group differences in gender (p < 0.001), where the
DLB subgroup had a higher number of men compared to AD.
In the DLB subgroup, the baseline NPI total score was higher (p
= 0.006), but MMSE at baseline was comparable between AD
and DLB patients (p = 0.966). Figure 1 shows the number of
individuals at each time point of the study including dropouts
due to death and loss to follow-up. The dropout rate at the latest
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FIGURE 1 | Flowchart of patients at each time point of the study including
dropouts. AD, Alzheimer’s disease; DLB, Dementia with Lewy bodies; Loss
FU, Loss to follow-up.
follow-up examination was 62.9% (n = 56), especially due to
death, which represents the 64.3% (n = 36) among the causes
of dropout.
Amygdala Volume at Baseline
Figure 2 illustrates the values of the intracranial volume-
normalized amygdala in the total sample and by diagnosis
subgroup. Intracranial volume-normalized amygdala was
comparable between the AD and the DLB subgroups (t =
−0.699, p= 0.487). Similar results were obtained when including
age, gender, and center of sMRI acquisition as covariates
(ANCOVA – PTukey = 0.569) (Table 1).
Significant group differences were observed for the center
of sMRI acquisition (t-test, p < 0.001) but these differences
disappeared (ANCOVA, p = 0.205) after controlling for age,
gender, diagnosis proportion in each center, as well as age
∗ gender, center ∗ diagnosis, and center ∗ age interactions
(supplementary Figure 1 and supplementary table 1).
Descriptive statistics of the intracranial volume-normalized
amygdala by gender are presented in supplementary Figure 2
and supplementary table 2.
NPS Over Time
Detailed graphical abstract of the frequency of clinically
relevant symptoms is presented in Figure 3, as well as
supplementary table 3. Figure 3 depicts the frequency (in
percent of symptomatic) of individuals with clinically relevant
NPS (i.e., a domain score ≥4) at each time point of the
study. Overall, the most frequent symptom in the total sample
was apathy.
At baseline, the more frequent clinically relevant symptoms
were apathy (30.3%), followed by depression (19.1%) and
irritability (18%), whereas euphoria (0%), agitation (5.6%), and
disinhibition (7.9%) were the less frequent clinically relevant
symptoms. Similarly, at the first annual follow-up, apathy
(39.3%), depression (21.4%), and irritability (19.1%) were the
more frequent clinically relevant symptoms, while euphoria
(3.4%), agitation (11.2%), and disinhibition (4.5%) were the less
frequently presented. At the second annual follow-up, apathy
was consistently the most presented symptom (47.6%), followed
by aberrant motor behavior (32.9%), and depression (25.6%),
while clinically relevant euphoria (0%), hallucinations (12.2%),
and agitation (13.4%) were the less presented symptoms. In
line with this, the higher frequency of presentation at the
third annual follow-up was accounted by clinically relevant
apathy (53.4%), aberrant motor behavior (32.9%), and depression
(26%), but clinically relevant euphoria (4.1%), disinhibition
(11%), and delusions (13.7%) were the less frequently presented
symptoms. At the fourth annual follow-up, the increasing trend
of presenting clinically relevant apathy (48.3%) and aberrant
motor behavior (31%) was slightly reduced, but the frequency
of clinically relevant depression augmented (27.6%). Besides,
clinically relevant euphoria (5.7%), disinhibition (12.1%), and
delusions (15.5%) were the less presented symptoms. Finally,
at the end of follow-up, clinically relevant apathy (48.3%),
irritability (33.3%), and aberrant motor behavior (27.3%)
were the more frequent symptoms whereas euphoria (6.1%),
delusions (18.2%), and depression (18.2%) were symptoms
with the lower frequency of presentation (Figure 3A and
supplementary table 3).
In both AD and DLB subgroups, the most frequent symptom
during the follow-up was apathy. In DLB patients, the frequency
of hallucinations was greater when compared to AD, while
aberrant motor behavior was more common in the AD subgroup
(Figure 3B, C and supplementary table 3).
These results were consistent with previously published
analyses of the total DemVest cohort (17, 18).
Association Between Amygdala Baseline
Volume and Trajectories of Global NPS
In an unadjusted model with time and center as predictors,
the intracranial volume-normalized amygdala had a significant
association with the NPI total score (fixed effect—FE—of −0.14,
95% confidence interval [−0.25, −0.02], p = 0.014, q = 0.041).
Table 2A summarizes the results of the partly adjusted (Model 1)
and fully adjusted model (Model 2) for predicting trajectories of
the NPI total score in the total sample.
A partly adjusted model showed that the intracranial volume-
normalized amygdala had a significant effect over the NPI
total score (FE = −0.14 [−0.25, −0.04], p = 0.049), but this
effect was no longer significant after multiple testing correction
(q = 0.091). A fully adjusted model did not show significant
findings, but a significant effect of MMSE was observed as
reported in Table 2A, Model 2.
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FIGURE 2 | Amygdala volumes after normalization for total intracranial volume in the total sample as well as the AD and DLB groups. Intracranial volume-normalized
amygdala (i.e., [Total amygdala volume in mm3/total intracranial volume in mm3 ] * 100%). AD, Alzheimer’s disease; DLB, Dementia with Lewy bodies; ICV, Total
intracranial volume in mm3.
Association Between Amygdala Baseline
Volume and Trajectories of Various NPS
Figure 4 summarizes the results of the unadjusted, partly
adjusted, and fully adjusted models for predicting trajectories
of NPS in the total sample. The odds ratio (OR) refers to the
risk of being in a one-level higher group on the ordinal NPI
domains (i.e., presenting mild symptoms or developing clinically
relevant symptoms).
The unadjusted model showed that patients with higher
intracranial volume-normalized amygdala had a reduced odds
for presenting mild symptoms of agitation/aggression or
developing clinically relevant agitation/aggression over 5 years
(OR = 0.55, 95% confidence interval [0.32, 0.84], p = 0.006,
q= 0.030). Similar results were obtained for agitation/aggression
in the partly adjusted model (OR = 0.54 [0.36, 0.80], p = 0.002,
q= 0.018), as well as in the fully adjustedmodel (OR= 0.62 [0.43,
0.90], p= 0.011, q= 0.038).
Besides, those patients with greater intracranial volume-
normalized amygdala had an increased odds for presenting
mild symptoms of depression or developing clinically relevant
depression as observed in the fully adjusted model (OR = 1.49
[1.09, 2.04], p = 0.013, q = 0.040). Consistent results were
observed in the unadjusted (OR = 1.41 [1.04, 1.90], p = 0.026,
q= 0.061) and partly adjusted models for depression (OR= 1.37
[1.03, 1.80], p = 0.034, q = 0.070) with a trend to significance in
the multiple testing-corrected q-values.
In addition, the partly adjusted models showed lower
odds for presenting mild symptoms of apathy or developing
clinically relevant apathy trajectories in those patients with
higher amygdala volumes (OR = 0.67 [0.46, 0.97], p = 0.033).
However, these results were not significant following correction
for multiple testing (q= 0.069).
No other NPI domains were significantly predicted by the
intracranial volume-normalized amygdala in the main analysis.
Association Between Amygdala Baseline
Volume and Trajectories of Global
Cognition
The unadjusted model showed the interaction of intracranial
volume-normalized amygdala and time interaction (FE = 0.70
[0.24, 1.16], p = 0.003, q = 0.020, see Table 2B, Model 3).
After adjusting for age, gender, diagnosis, and their significant
time interactions, the intracranial volume-normalized amygdala
showed a significant FE of 0.66 [0.29, 1.03], p= 0.001, q= 0.010,
Table 2B, Model 4.
In the total sample, Figure 5A shows the predicted MMSE
score over 5 years according to the intracranial volume-
normalized amygdala. Patients with higher intracranial
volume-normalized amygdala had lesser MMSE decline per
year after adjusting for the time in study, center of sMRI
acquisition, age, gender, and diagnosis. Consistently, Figure 5B
depicts the predicted MMSE score over 5 years according to
the intracranial volume-normalized amygdala in both AD
and DLB subgroups. In the DLB subgroup, the predicted
MMSE score over 5 years according to the intracranial
volume-normalized amygdala was lower compared to the
AD subgroup.
Exploratory Analyses by Diagnosis
Subgroup
Supplementary Table 4 summarizes the results of the
additional exploratory analyses conducted separately in
the DLB and AD subgroups. The intracranial volume-
normalized amygdala showed a statistically significant
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FIGURE 3 | Trajectories of clinically relevant neuropsychiatric symptoms in the total sample, AD and DLB groups. NPS, Neuropsychiatric symptoms; NPI,
Neuropsychiatric Inventory; BL, Baseline. Trajectories of clinically relevant NPS in the total sample (A), the AD subgroup (B), and the DLB subgroup (C).
effect predicting the MMSE ∗ time interaction (representing
points decline per year per unit of amygdala volume) in
AD (FE = 0.53 [0.13, 0.93], p = 0.010), and stronger
in DLB (FE = 1.19 [0.31, 2.07], p = 0.008). The
NPI total was only significantly predicted in the DLB
subgroup (FE=−0.13 [−0.25,−0.02], p= 0.027).
The lower odds of presenting mild symptoms of agitation
or developing clinically relevant agitation with higher amygdala
volumes were similar in AD (OR = 0.57 [0.36, 0.90],
p = 0.015) and DLB (OR = 0.47 [0.18, 1.22], p =
0.120) but not significant in DLB, likely due to the small
sample size. Similar findings were observed in both AD
(OR = 1.45 [1.02, 2.06], p = 0.041) and DLB groups (OR
= 1.38 [0.83, 2.29], p = 0.211) for the higher odds of
presenting mild symptoms of depression or developing clinically
relevant depression.
Interestingly, the DLB subgroup showed a reduced odds
of presenting mild symptoms of hallucinations or developing
clinically relevant hallucinations in those individuals with
a higher intracranial volume-normalized amygdala (OR =
0.49 [0.31, 0.78], p = 0.002), which was not observed
in AD (OR = 0.94 [0.49, 1.78], p = 0.845). Intracranial
volume-normalized amygdala was not a significant predictor
for other NPS.
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TABLE 2A | Amygdala volume and the Neuropsychiatric Inventory total score over 5 years.
Model 1a Model 2a
FE 95% CI p-value q-value FE 95% CI p-value q-value
Time 0.14 0.08, 0.19 < 0.001 0.07 0.02, 0.13 0.010
Centerb
1 −0.22 −0.56, 0.13 0.223 −0.15 −0.49, 0.19 0.380
2 −0.47 −0.82, −0.12 0.008 −0.44 −0.80, −0.08 0.017
Age 0.03 0.01, 0.04 0.002 0.02 0.01, 0.04 0.006
Gender (female) −0.22 −0.47, 0.03 0.082 −0.21 −0.44, 0.02 0.088
DLB 0.19 −0.04, 0.42 0.102 0.18 −0.03, 0.39
MMSE −0.03 −0.04, −0.02 <0.001
Amygdala (%ICV) −0.14 −0.25,−0.04 0.049 0.091 −0.10 −0.22, 0.01 0.072 0.118
TABLE 2B | Amygdala volume and MMSE over 5 years.
Model 3c Model 4c
FE 95% CI p-value q-value FE 95% CI p-value q-value
Time (T) −3.01 −3.41, −2.59 <0.001 −2.64 −3.08, −2.20 <0.001
Centerb
1 0.25 −2.40, 2.90 0.852 1.20 −1.49, 3.91 0.381
2 −0.32 −2.77, 2.13 0.797 0.16 −2.22, 2.55 0.894
Age −0.16 −0.23, −0.09 <0.001
Age × T 0.07 0.01, 0.14 0.025
Gender (female) 0.66 −0.69, −2.01 0.336
Diagnosis (DLB) 0.74 −0.65, 2.13 0.295
Diagnosis (DLB) × T −1.07 −1.99, −1.16 0.022*
Amygdala (% ICV) 0.06 −0.95, 1.07 0.906 NA 0.16 −0.81, 1.12 0.747 NA
Amygdala (% ICV) × T 0.70 0.24, 1.16 0.003 0.020 0.66 0.29, 1.03 0.001 0.010
DLB, Dementia with Lewy bodies; FE, Fixed effect; CI, Confidence interval; MMSE, Mini-mental State Examination; NPI, Neuropsychiatric inventory; ICV, Total intracranial volume; T, Time.
aGeneralized mixed-effects model with the absolute NPI total score (added a constant of one to provide strictly positive distribution) at each time point of the study as the dependent
variable, and intracranial volume-normalized amygdala as independent variable, based on gamma distribution and log-link with random intercepts and slopes in an unstructured
variance–covariance matrix with covariates as listed. In a model with time and center as predictors (not in Table), Amygdala (% ICV) had an FE of −0.14 [−0.25, −0.02], p = 0.014,
q = 0.041.
bTwenty-three participants from reference center (Bergen), 11 in center coded as 1 (Haugesund), 55 in center coded as 2 (Stavanger).
cLinear mixed-effects model with the absolute MMSE score at each time point of the study as the outcome variable, intracranial volume-normalized amygdala as independent variable,
random intercepts, and slopes in an unstructured variance–covariance matrix and covariates as listed.
Time interactions with intracranial volume-normalized amygdala were also evaluated in the NPI total score and the MMSE models based on the Akaike Information Criterion (AIC) and
the Bayesian Information Criterion (BIC). Any significant interaction was included in the above models.
p-values and q < 0.05 are printed in bold. Multiple testing corrected p-values (q-values) are listed only for Amygdala (% ICV) (Models 1 and 2), or its interaction with time (Models 3
and 4).
DISCUSSION
This study analyzed the associations between amygdala volume
and NPS in AD and DLB, over 5 years of follow-up. We have
found that amygdala volumes were comparable between AD and
DLB patients at the mild stage of dementia. Greater baseline
amygdala volume in patients with mild dementia was associated
with lower odds for developing agitation/aggression symptoms.
Besides, higher odds for developing symptoms of depressionwere
associated with greater baseline amygdala volume.
The reduction of amygdala volume has been widely studied
in AD, but few cross-sectional studies have compared amygdala
volume in AD and DLB (45–47), reporting conflicting results
(48) that might be attributed to differences in study designs and
methods of analysis. In line with our findings, a preliminary study
with a matched-sample design combined manual and automatic
segmentation and did not find group differences in the amygdala
volumes of AD and DLB patients (47). By contrast, two studies
found larger amygdala volumes in DLB (45–47), but the lack of
adjustment for gender could have influenced their results.
Amygdala atrophy has been demonstrated in moderate and
severe AD, but it is also prominent in the early stages of AD
(7, 49). Functional and structural brain abnormalities may reflect
the neuropathological features of dementia (i.e., Lewy bodies,
tau, and amyloid-beta), and a relationship between the burden of
Lewy bodies in the amygdala and reduced amygdala volume has
Frontiers in Neurology | www.frontiersin.org 8 July 2021 | Volume 12 | Article 679984
Jaramillo-Jimenez et al. Amygdala and Neuropsychiatric Symptoms in Dementia
FIGURE 4 | Association between amygdala volume and trajectories of neuropsychiatric symptoms in the total sample. NPI, Neuropsychiatric inventory; OR, Odds
ratios; CI, Confidence interval. Unadjusted model included amygdala and time as covariates; partly adjusted model also included age, gender, and diagnosis as
covariates; fully adjusted model included MMSE score over 5 years as covariate. The OR (95% CI) refers to the risk of being in a one-level higher group on each of the
ordinal NPI items (i.e., presenting mild symptoms, or developing a clinically relevant symptom). Multiple testing-corrected p-values (q-values) > 0.1 are listed.
been demonstrated in postmortem studies (48). Examining brain
volumes in key regions can contribute to the understanding of
the structural substrates of different NPS in dementia.
In AD, one longitudinal (2-year study) and several cross-
sectional studies suggest close relationships between amygdala
volume, cognitive performance, and presence of NPS (7, 9, 19,
49), including agitation/aggression (7, 9, 50). However, none of
the available studies have investigated the amygdala volume as
an early marker of long-term risk of NPS, and follow-up periods
are relatively smaller compared to ours, which can affect the
results considering the within-subject fluctuation of NPS over
time (17).
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FIGURE 5 | Association between amygdala volume and trajectories of global cognition in the total sample and each diagnosis subgroup. MMSE, Mini-mental state
examination; SD: Standard deviation. (A) Predictions in the total sample. (B) Predictions in the AD and DLB subgroups. This plot is based on the estimations
presented in Table 2B, Model 4 (adjusted for time in study, age, gender, diagnosis, and center of sMRI acquisition).
We found that baseline amygdala volume had a significant
inverse association with the trajectories of agitation/aggression
in the total sample, as well as in the AD subgroup. This
might reflect damage in circuits underlying behavioral and
cognitive avoidance, which could explain clinical features
present in agitated/aggressive patients such as overestimation
and overreaction to threats, difficulties to modulate strong
emotional responses, or increased vigilance and reactivity
(9, 50). Aggression circuits involve the amygdala, as well
as the insular, anterior cingulate, and orbitofrontal cortexes,
which are also described in apathy (9, 19, 50). Thus,
an imbalance between the default mode network and the
salience network, characterized by increased connectivity in
the latter, is hypothesized in those patients with agitation and
apathy (9).
An association between baseline amygdala volume and
the trajectories of depression was also observed in this
study. Of note, this has not been previously reported in
dementia patients with longitudinal data. Prior reports in
young patients or patients with a first depressive episode
linked depression to enlarged amygdala volume (51, 52).
Nevertheless, conflicting results also reported an opposite
direction for this relationship (53). Large meta-analyses
concluded that a direct association between amygdala
volume and major depression was particularly observed
in depressed patients with comorbid anxiety (10), or
those who were under antidepressive treatment (13). In
AD, the presence of concomitant Lewy pathology in the
amygdala increases the risk for major depression (54).
Therefore, longitudinal designs will contribute to filling
current knowledge gaps in specific imaging markers of
depression in patients with cognitive decline, those with
a history of early- and late-onset depression, and healthy
older adults.
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We adjusted the final models for cognitive decline under
the assumption that cognitive deterioration could confound the
amygdala volume/NPS association. However, it is equally if not
more plausible that cognitive deterioration is an intermediate
variable (55), in which case the partially adjusted models would
be more appropriate. Therefore, we highlight the findings of
the partly adjusted models in agitation/aggression, which are
robust across all levels of adjustment and are supported by
the available evidence. Also, interesting findings were observed
in the partly adjusted models for the trajectories of apathy
and depression with a trend to significance after correction for
multiple testing.
Previously published cross-sectional evidence has linked
apathy and the amygdala (16, 19, 56). In the behavioral
variant of frontotemporal dementia, apathy has been considered
the result of a disruption of emotional-affective mechanisms
functionally linked to the ventromedial prefrontal cortex, the
amygdala, and the ventral striatum (57). However, a recent review
has pointed out that both emotional-affective and cognitive
aspects may lead to impaired motivation and reduced self-
generated goal-oriented behaviors that depend on the integrity
of cortical and subcortical structures connecting the limbic
system and the prefrontal cortex (56). Dopaminergic deficits in
the mesolimbic system, especially in the basal amygdala, have
also been suggested as a possible underlying mechanism for
apathy (58).
Exploratory subgroup analyses showed consistent results in
the AD subgroup for agitation and depression. In the DLB group,
amygdala volume seems to be associated with the trajectories
of hallucinations, but not with other NPS. Remarkably, visual
hallucinations have been described as a strong predictor of
Lewy pathology; thus, increased burden of Lewy bodies in
the amygdala has been reported in DLB patients with visual
hallucinations (59).
In conclusion, greater amygdala volume in mild dementia is
associated with lower odds of developing agitation/aggression
but higher odds of developing depression symptoms during the
5-year study period (particularly in AD). We encourage future
works studying NPS in dementia to examine the external validity
of our findings.
STRENGTHS AND LIMITATIONS
Assessing NPS through a standardized, valid, reliable, and widely
available instrument contributes to the reproducibility and
external validity of our findings. From the clinical standpoint,
defining NPS as “clinically relevant” favors a consistent
distinction between overlapping symptoms such as depression
and apathy (17); it also facilitates the interpretation of the
results. These cutoffs have been widely used in previously
published studies (17, 18, 29–32) but have not been validated yet.
Conversely, the NPI does not capture the whole spectrum of NPS
of dementia and was based on the carer report.
We included patients with a sufficiently long follow-up,
considering NPS present from the early to the severe stage
of dementia. However, sMRI segmentation from other causes
of dementia with remarkable NPS, such as frontotemporal
dementia, was not available. In addition, the small sample
size and rate of dropouts due to mortality, especially in the
DLB group, could lead to underestimations of the trajectories
of NPS. Besides, a potential recruitment bias may be present
in our data due to the referrals of patients with complicated
dementia or NPS from primary care units. However, psychiatric,
geriatric, and neurology clinics, as well as GPs, were invited to
refer every patient with suspected dementia to minimize this
potential source of bias. Also, no control group was available for
contrasting our results with normal aging, but clinically relevant
NPS were not expected in normal aging (31).
On the other hand, preliminary reports have shown that
the amygdala volumes based on the FreeSurfer pipeline have
higher validity (i.e., strongly correlations to manual tracing)
than other automatic segmentation tools (60, 61). Nevertheless,
automatic methods for sMRI segmentation seem to overestimate
amygdala volumes, but this does not necessarily imply a lack of
validity with adequate visual quality control (61). Also, we are
aware of various normalization methods for structural volumes
that control for gender differences and head size. However, we
conducted amygdala/ICV ratios as it has been demonstrated
to control for gender differences in the amygdala volume and
facilitate interpretation of the results (36, 37). Further studies
with standardized and harmonized normalization protocols can
address these limitations. Finally, longitudinal sMRI could be
used to estimate atrophy rates and elucidate the potential effects
of volume changes over time and the severity of NPS.
DATA AVAILABILITY STATEMENT
The datasets presented in this article are not readily available
because we do not have ethical approval to freely share data to
non-related groups. Requests to access the datasets should be
directed to Dag Aarsland, daarsland@gmail.com.
ETHICS STATEMENT
The studies involving human participants were reviewed
and approved by Stavanger University Hospital. The
patients/participants provided their written informed consent to
participate in this study.
AUTHOR CONTRIBUTIONS
AJ-J: conception of work, visualization, formal analysis,
methodology, preparation of the initial draft, writing, reviewing,
and approval. LG and DT-R: formal analysis, methodology,
writing, reviewing, editing, and approval. MB: conception of
work, writing, reviewing, and approval. DF, KB, KO, and DA:
supervision, methodology, visualization, writing, reviewing, and
approval. All authors contributed to the article and approved the
submitted version.
Frontiers in Neurology | www.frontiersin.org 11 July 2021 | Volume 12 | Article 679984
Jaramillo-Jimenez et al. Amygdala and Neuropsychiatric Symptoms in Dementia
FUNDING
This paper represents independent research supported by the
Norwegian government, through hospital owner Helse Vest
(Western Norway Regional Health Authority). Also, this work
is funded by the National Institute for Health Research (NIHR)
Biomedical Research Centre at South London and Maudsley
NHS Foundation Trust, King’s College London, and Center for
Innovative Medicine (CIMED). The views expressed are those of
the author(s) and not necessarily those of the NHS, the NIHR, or
the Department of Health and Social Care.
ACKNOWLEDGMENTS
We want to thank all the participants, researchers,
and technical staff who have made the DemVest
study possible.
SUPPLEMENTARY MATERIAL




1. Chow N, Aarsland D, Honarpisheh H, Beyer MK, Somme JH, Elashoff
D, et al. Comparing hippocampal atrophy in Alzheimer’s dementia and
dementia with lewy bodies. Dement Geriatr Cogn Disord. (2012) 34:44–
50. doi: 10.1159/000339727
2. Oppedal K, Ferreira D, Cavallin L, Lemstra AW, ten Kate M, Padovani A, et
al. A signature pattern of cortical atrophy in dementia with lewy bodies: a
study on 333 patients from the european dLB consortium.Alzheimers Dement.
(2019) 15:400–9. doi: 10.1016/j.jalz.2018.09.011
3. Dawe RJ, Bennett DA, Schneider JA, Arfanakis K. Neuropathologic correlates
of hippocampal atrophy in the elderly: a clinical, pathologic, postmortem
mRI study. PLoS ONE. (2011) 6:e26286. doi: 10.1371/journal.pone.00
26286
4. Peng GP, Feng Z, He FP, Chen ZQ, Liu XY, Liu P, et al. Correlation of
hippocampal volume and cognitive performances in patients with either
mild cognitive impairment or Alzheimer’s disease. CNS Neurosci Ther. (2015)
21:15–22. doi: 10.1111/cns.12317
5. Oler JA. “Medial Temporal Lobe,” in Encyclopedia of Clinical Neuropsychology,
eds J. S. Kreutzer, J. DeLuca, B. Caplan (New York, NY: Springer New York),
1538–40.
6. Raslau FD, Mark IT, Klein AP, Ulmer JL, Mathews V, Mark LP. Memory part
2: the role of the medial temporal lobe. Am J Neuroradiol. (2015) 36:846.
doi: 10.3174/ajnr.A4169
7. Poulin SP, Dautoff R, Morris JC, Barrett LF, Dickerson BC.
Amygdala atrophy is prominent in early Alzheimer’s disease and
relates to symptom severity. Psychiatry Res Neuroimaging. (2011)
194:7–13. doi: 10.1016/j.pscychresns.2011.06.014
8. Rodríguez JJ, Noristani HN, Verkhratsky A. The serotonergic
system in ageing and Alzheimer’s disease. Prog Neurobiol. (2012)
99:15–41. doi: 10.1016/j.pneurobio.2012.06.010
9. Rosenberg PB, Nowrangi MA, Lyketsos CG. Neuropsychiatric symptoms in
Alzheimer’s disease: what might be associated brain circuits?Mol Aspects Med.
(2015) 43–44:25–37. doi: 10.1016/j.mam.2015.05.005
10. Espinoza Oyarce DA, Shaw ME, Alateeq K, Cherbuin N. Volumetric
brain differences in clinical depression in association with anxiety: a
systematic review with meta-analysis. J Psychiatry Neurosci. (2020) 45:406–
29. doi: 10.1503/jpn.190156
11. Ho NF, Chong PLH, Lee DR, Chew QH, Chen G, Sim K. The amygdala in
schizophrenia and bipolar disorder: a Synthesis of structural mRI, diffusion
tensor imaging, and resting-State functional connectivity findings. Harv Rev
Psychiatry. (2019) 27:150–64. doi: 10.1097/HRP.0000000000000207
12. Anticevic A, Van Snellenberg JX, Cohen RE, Repovs G, Dowd EC, Barch DM.
Amygdala recruitment in schizophrenia in response to aversive emotional
material: a meta-analysis of neuroimaging studies. Schizophr Bull. (2012)
38:608–21. doi: 10.1093/schbul/sbq131
13. Hamilton JP, Siemer M, Gotlib IH. Amygdala volume in major depressive
disorder: a meta-analysis of magnetic resonance imaging studies. Mol
Psychiatry. (2008) 13:993–1000. doi: 10.1038/mp.2008.57
14. Wright CI, Dickerson BC, Feczko E, Negeira A, Williams D. A functional
magnetic resonance imaging study of amygdala responses to human faces
in aging and mild Alzheimer’s disease. Biol Psychiatry. (2007) 62:1388–
95. doi: 10.1016/j.biopsych.2006.11.013
15. Davidson RJ. Anxiety and affective style: role of prefrontal
cortex and amygdala. Biol Psychiatry. (2002) 51:68–
80. doi: 10.1016/S0006-3223(01)01328-2
16. Kile SJ, Ellis WG, Olichney JM, Farias S, Decarli C. Alzheimer
abnormalities of the amygdala with klüver-Bucy syndrome symptoms:
an amygdaloid variant of alzheimer disease. Arch Neurol. (2009)
66:125–29. doi: 10.1001/archneurol.2008.517
17. Vik-Mo AO, Giil LM, Ballard C, Aarsland D. Course of neuropsychiatric
symptoms in dementia: 5-year longitudinal study. Int J Geriatr Psychiatry.
(2018) 33:1361–9. doi: 10.1002/gps.4933
18. Vik-Mo AO, Giil LM, Borda MG, Ballard C, Aarsland D. The individual
course of neuropsychiatric symptoms in people with Alzheimer’s and lewy
body dementia: 12-year longitudinal cohort study. Br J Psychiatry. (2020)
216:43–8. doi: 10.1192/bjp.2019.195
19. Tascone L dos S, Bottino CM de C. Neurobiologia dos sintomas
neuropsiquiátricos na doença de Alzheimer: uma revisão crítica com
foco na neuroimagem. Dement e Neuropsychol. (2013) 7:236–43.
doi: 10.1590/S1980-57642013DN70300002
20. Aarsland D, Rongve A, Piepenstock Nore S, Skogseth R, Skulstad S, Ehrt
U, et al. Frequency and case identification of dementia with lewy bodies
using the revised consensus criteria. Dement Geriatr Cogn Disord. (2008)
26:445–52. doi: 10.1159/000165917
21. Borda MG, Jaramillo-Jimenez A, Tovar-Rios DA, Ferreira D, Garcia-
Cifuentes E, Vik-Mo AO, et al. Hippocampal subfields and decline in
activities of daily living in Alzheimer’s disease and dementia with lewy
bodies. Neurodegener Dis Manag. (2020) 10:357–67. doi: 10.2217/nmt-2020-0
039
22. Diagnostic statistical manual of mental disorders: DSM-IV. 4th Edn.
Washington, DC : American Psychiatric Association, (1994) Available online
at: https://search.library.wisc.edu/catalog/999733358502121
23. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman
H, et al. Diagnosis and management of dementia with lewy
bodies: third report of the dLB consortium. Neurology. (2005)
65:1863–72. doi: 10.1212/01.wnl.0000187889.17253.b1
24. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan
EM. Clinical diagnosis of Alzheimer’s disease: report of the nINCDS-
ADRDA work group? under the auspices of department of health and
human services task force on Alzheimer’s disease. Neurology. (1984) 34:939–
44. doi: 10.1212/WNL.34.7.939
25. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical
method for grading the cognitive state of patients for the clinician. J Psychiatr
Res. (1975) 12:189–98. doi: 10.1016/0022-3956(75)90026-6
26. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new
clinical scale for the staging of dementia. Br J Psychiatry. (1982) 140:566–
572. doi: 10.1192/bjp.140.6.566
27. Skogseth R, Hortobágyi T, Soennesyn H, Chwiszczuk L, Ffytche D,
Rongve A, et al. Accuracy of clinical diagnosis of dementia with
lewy bodies versus neuropathology. J Alzheimer’s Dis. (2017) 59:1139–
52. doi: 10.3233/JAD-170274
Frontiers in Neurology | www.frontiersin.org 12 July 2021 | Volume 12 | Article 679984
Jaramillo-Jimenez et al. Amygdala and Neuropsychiatric Symptoms in Dementia
28. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi
DA, Gornbein J. The neuropsychiatric inventory: comprehensive
assessment of psychopathology in dementia. Neurology. (1994)
44:2308–14. doi: 10.1212/WNL.44.12.2308
29. Zhang M, Wang H, Li T, Yu X. Prevalence of neuropsychiatric symptoms
across the declining memory continuum: an observational study in a
memory clinic setting. Dement Geriatr Cogn Dis Extra. (2012) 2:200–
8. doi: 10.1159/000338410
30. Teipel SJ, Thyrian JR, Hertel J, Eichler T, Wucherer D, Michalowsky
B, et al. Neuropsychiatric symptoms in people screened positive
for dementia in primary care. Int Psychogeriatrics. (2015)
27:39–48. doi: 10.1017/S1041610214001987
31. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, Dekosky S.
Prevalence of neuropsychiatric symptoms in dementia and mild cognitive
impairment: results from the cardiovascular health study. J Am Med Assoc.
(2002) 288:1475–83. doi: 10.1001/jama.288.12.1475
32. Aalten P, Verhey FRJ, Boziki M, Bullock R, Byrne EJ, Camus V, et
al. Neuropsychiatric syndromes in dementia: results from the european
alzheimer disease consortium: part i. Dement Geriatr Cogn Disord. (2007)
24:457–63. doi: 10.1159/000110738
33. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove
C, et al. Whole brain segmentation: automated labeling of
neuroanatomical structures in the human brain. Neuron. (2002)
33:341–55. doi: 10.1016/S0896-6273(02)00569-X
34. Fischl B, van der Kouwe A, Destrieux C, Halgren E, Ségonne F, Salat DH, et
al. Automatically parcellating the human cerebral cortex. Cereb Cortex. (2004)
14:11–22. doi: 10.1093/cercor/bhg087
35. Jovicich J, Czanner S, Greve D, Haley E, van der Kouwe A, Gollub R, et
al. Reliability in multi-site structural mRI studies: effects of gradient non-
linearity correction on phantom and human data.Neuroimage. (2006) 30:436–
43. doi: 10.1016/j.neuroimage.2005.09.046
36. Whitwell JL, Crum WR, Watt HC, Fox NC. Normalization of cerebral
volumes by use of intracranial volume: implications for longitudinal
quantitative mR imaging. Am J Neuroradiol. (2001) 22:1483.
37. Voevodskaya O. The effects of intracranial volume adjustment approaches on
multiple regional mRI volumes in healthy aging andAlzheimer’s disease. Front
Aging Neurosci. (2014) 6:264. doi: 10.3389/fnagi.2014.00264
38. Brown H, Prescott R. Applied Mixed Models in Medicine, 3rd Edn. Chichester,
England:Wiley Blackwell. (2015).
39. Storey JD. A direct approach to false discovery rates. J R Stat Soc Ser B Stat
Methodol. (2002) 64:479–98. doi: 10.1111/1467-9868.00346
40. Strimmer K. fdrtool: a versatile r package for estimating local and
tail area-based false discovery rates. Bioinformatics. (2008) 24:1461–2.
doi: 10.1093/bioinformatics/btn209
41. Ibrahim JG, Molenberghs G. Missing data methods in longitudinal studies: a
review. Test. (2009) 18:1–43. doi: 10.1007/s11749-009-0138-x
42. Wickham H. ggplot2: Elegant Graphics for Data Analysis. (2016) Available
online at: https://ggplot2.tidyverse.org
43. Waskom M. Seaborn: statistical data visualization. J. Open Source Soft.
6(60):3021. https://doi.org/10.21105/joss.03021
44. Vandenbroucke JP, Von Elm E, Altman DG, Gøtzsche PC, Mulrow CD,
Pocock SJ, et al. Strengthening the reporting of observational studies in
epidemiology (STROBE): explanation and elaboration. PLoS Med. (2007)
4:1628–1654. doi: 10.1371/journal.pmed.0040297
45. Burton EJ, Karas G, Paling SM, Barber R, Williams ED, Ballard CG, et
al. Patterns of cerebral atrophy in dementia with lewy bodies using voxel-
Based morphometry. Neuroimage. (2002) 17:618–30. doi: 10.1006/nimg.200
2.1197
46. Barber R, Ballard C, McKeith IG, Gholkar A, O’Brien JT. MRI volumetric
study of dementia with lewy bodies: a comparison with aD and vascular
dementia. Neurology. (2000) 54:1304–9. doi: 10.1212/WNL.54.6.1304
47. Hashimoto M, Kitagaki H, Imamura T, Hirono N, Shimomura T,
Kazui H, et al. Medial temporal and whole-brain atrophy in dementia
with lewy bodies: a volumetric mRI study. Neurology. (1998) 51:357–
62. doi: 10.1212/WNL.51.2.357
48. Burton EJ, Mukaetova-Ladinska EB, Perry RH, Jaros E, Barber
R, O’Brien JT. Neuropathological correlates of volumetric mRI in
autopsy-confirmed lewy body dementia. Neurobiol Aging. (2012)
33:1228–36. doi: 10.1016/j.neurobiolaging.2010.12.015
49. Klein-Koerkamp Y, Heckemann R, Ramdeen K, Moreaud O, Keignart
S, Krainik A, etal. Disease Neuroimaging Initiative for the. Amygdalar
Atrophy in Early Alzheimer’s Disease. Curr Alzheimer Res. (2014) 11:239–
52. doi: 10.2174/1567205011666140131123653
50. Trzepacz PT, Yu P, Bhamidipati PK, Willis B, Forrester T, Tabas L, et al.
Frontolimbic atrophy is associated with agitation and aggression in mild
cognitive impairment and Alzheimer’s disease. Alzheimers Dement. (2013)
9:S95–S104.e1. doi: 10.1016/j.jalz.2012.10.005
51. Frodl T, Meisenzahl EM, Zetzsche T, Born C, Jäger M, Groll C, et al. Larger
amygdala volumes in first depressive episode as compared to recurrent
major depression and healthy control subjects. Biol Psychiatry. (2003) 53:338–
44. doi: 10.1016/S0006-3223(02)01474-9
52. Lange C, Irle E. Enlarged amygdala volume and reduced hippocampal volume
in young women with major depression. Psychol Med. (2004) 34:1059–
64. doi: 10.1017/S0033291703001806
53. Omura K, Constable RT, Canli T. Amygdala gray matter concentration is
associated with extraversion and neuroticism. Neuroreport. (2005) 16:1905–
8. doi: 10.1097/01.wnr.0000186596.64458.76
54. Lopez OL, Becker JT, Sweet RA, Martin-Sanchez FJ, Hamilton
RL. Lewy bodies in the amygdala increase risk for major
depression in subjects with alzheimer disease. Neurology. (2006)
67:660–5. doi: 10.1212/01.wnl.0000230161.28299.3c
55. Ananth C V, Schisterman EF. Confounding, causality and confusion:
the role of intermediate variables in interpreting observational studies
in obstetrics hHS public access. Am J Obs Gynecol. (2017) 217:167–
75. doi: 10.1016/j.ajog.2017.04.016
56. Pagonabarraga J, Kulisevsky J, Strafella AP, Krack P. Apathy in Parkinson’s
disease: clinical features, neural substrates, diagnosis, and treatment. Lancet
Neurol. (2015) 14:518–31. doi: 10.1016/S1474-4422(15)00019-8
57. Quaranta D, Marra C, Rossi C, Gainotti G, Masullo C. Different apathy
profile in behavioral variant of frontotemporal dementia and Alzheimer’s
disease: a preliminary investigation. Curr Gerontol Geriatr Res. (2012)
2012:719250. doi: 10.1155/2012/719250
58. Le Heron C, Holroyd CB, Salamone J, Husain M. Brain
mechanisms underlying apathy. J Neurol Neurosurg Psychiatry. (2019)
90:302–12. doi: 10.1136/jnnp-2018-318265
59. O’brien J, Taylor JP, Ballard C, Barker RA, Bradley C, Burns A, Collerton
D, et al. Visual hallucinations in neurological and ophthalmological disease:
pathophysiology and management. J Neurol Neurosurg Psychiatry. (2020)
91:512–19. doi: 10.1136/jnnp-2019-322702
60. Morey RA, Petty CM, Xu Y, Pannu Hayes J, Wagner HR, Lewis D V.,
et al. A comparison of automated segmentation and manual tracing for
quantifying hippocampal and amygdala volumes.Neuroimage. (2009) 45:855–
866. doi: 10.1016/j.neuroimage.2008.12.033
61. Schoemaker D, Buss C, Head K, Sandman CA, Davis EP,
Chakravarty MM, et al. Hippocampus and amygdala volumes
from magnetic resonance images in children: assessing accuracy of
freeSurfer and fSL against manual segmentation. Neuroimage. (2016)
129:1–14. doi: 10.1016/j.neuroimage.2016.01.038
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2021 Jaramillo-Jimenez, Giil, Tovar-Rios, Borda, Ferreira, Brønnick,
Oppedal and Aarsland. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Neurology | www.frontiersin.org 13 July 2021 | Volume 12 | Article 679984
